Evidence map›Paper›PMID 32051020›Full record

ArticleTrials2020

Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebocontrolled, randomised, double blind, multi-centre study.

Frank Tegtmeier, Reinhard Schinzel, Ronny Beer, Diederik Bulters, Jean-Yves LeFrant, Joan Sahuquillo, Andreas Unterberg, Peter Andrews, Antonio Belli, Javier Ibanez and 6 more

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Nitric Oxide Synthase Inhibitors into the Clinic at Last.Handbook of experimental pharmacology · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 5 countries.

Frank Tegtmeiervasopharm GmbH, Würzburg, Germany.
Reinhard Schinzelvasopharm GmbH, Würzburg, Germany. schinzel@vasopharm.de.
Ronny BeerMedizinische Universität Innsbruck, Innsbruck, Austria.
Diederik BultersWessex Neurological Centre University Hospital, Southampton, UK.
Jean-Yves LeFrantHopital Universitaire Caremeau, Nimes, France.
Joan SahuquilloVall d'Hebron University Hospital, Barcelona, Spain.
Andreas UnterbergUniversitätsklinikum Heidelberg, Heidelberg, Germany.
Peter AndrewsWestern General Hospital Lothian University, Edinburgh, UK.
Antonio BelliQueen Elizabeth Hospital, Birmingham, UK.
Javier IbanezEspases University Hospital, Palma de Mallorca, Spain.
Alfonso LagaresHospital Universitario 12 de Octubre, Madrid, Spain.
Michael MokryLKH - Universitätsklinikum Graz, Graz, Austria.
Harald WillschkeMedizinische Universität Wien, Wien, Austria.
Charlotte FlühUniversitätsklinikum Schleswig-Holstein, Kiel, Germany.
Erich SchmutzhardMedizinische Universität Innsbruck, Innsbruck, Austria.
NOSTRA Investigators
Innsbruck Medical University · ATGraz University Hospital · ATHeidelberg University · DEQueen Elizabeth Hospital Birmingham · GBVasopharm (Germany) · DECentre Hospitalier Universitaire de Nîmes · FRHospital Universitario 12 De Octubre · ESUniversity Hospital Schleswig-Holstein · DEUniversity Hospital Southampton NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After publication of our article [1] the authors have notified us that one of the names has been incorrectly spelled.

Identifiers

PMID32051020
PMCPMC7014658
OpenAlexW3005436336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.